— Know what they know.
Not Investment Advice

MD NYSE

Pediatrix Medical Group, Inc.
1W: -8.3% 1M: -5.7% 3M: +14.4% YTD: +1.2% 1Y: +42.1% 3Y: +56.4% 5Y: -31.7%
$21.27
-0.28 (-1.30%)
 
Weekly Expected Move ±6.4%
$20 $21 $22 $24 $25
NYSE · Healthcare · Medical - Care Facilities · Alpha Radar Sell · Power 37 · $1.7B mcap · 81M float · 1.08% daily turnover · Short 66% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
40.4 / 100
NoneWeakNarrowWide
Primary source: Intangible Assets  ·  ROIC: 17.1%  ·  5Y Avg: 2.8%
Cost Advantage
52
Intangibles
55
Switching Cost
27
Network Effect
23
Scale
40
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. MD shows a Weak competitive edge (40.4/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Intangible Assets. ROIC of 17.1% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$24
Low
$24
Avg Target
$25
High
Based on 2 analysts since May 5, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 14Hold: 17Sell: 2Strong Sell: 0
Rating Summary
ConsensusHold
Avg Target$24.50
Analysts4
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-12 UBS $22 $25 +3 +6.7% $23.42
2026-05-08 Mizuho Securities $23 $24 +1 +4.7% $22.93
2026-04-20 Jefferies Jack Slevin $14 $27 +13 +16.3% $23.21
2026-02-24 UBS $23 $22 -1 +14.6% $19.20
2026-02-20 Deutsche Bank $8 $19 +11 +1.1% $18.80
2026-02-19 Truist Financial $24 $21 -3 +14.1% $18.41
2025-11-10 Truist Financial David MacDonald $17 $24 +7 +7.6% $22.30
2025-11-05 UBS Initiated $23 +7.2% $21.46
2025-10-14 Truist Financial David MacDonald $13 $17 +4 +6.0% $16.04
2024-10-07 Truist Financial David MacDonald $10 $13 +3 +7.2% $12.13
2024-09-26 Jefferies Jack Slevin Initiated $14 +24.3% $11.26
2024-08-15 Truist Financial David MacDonald Initiated $10 -1.6% $10.16
2024-06-07 Deutsche Bank Pito Chickering Initiated $8 +16.1% $6.89
2022-12-05 Credit Suisse $28 $27 -1 +65.8% $16.28
2022-08-11 Credit Suisse $30 $28 -2 +31.6% $21.27
2022-05-03 Credit Suisse Initiated $30 +57.7% $19.02
2022-05-02 Mizuho Securities Initiated $23 +19.2% $19.30
2022-04-27 Leerink Partners Initiated $24 +5.6% $22.73

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A
May 22, 2026
DCF
5
ROE
5
ROA
5
D/E
1
P/E
3
P/B
3
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. MD receives an overall rating of A. Strongest factors: DCF (5/5), ROE (5/5), ROA (5/5). Areas of concern: D/E (1/5).
Rating Change History
DateFromTo
2026-05-18 A- A
2026-05-11 A A-
2026-04-27 A- A
2026-04-21 A A-
2026-04-06 A- A

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

62 Grade A
Profitability
43
Balance Sheet
74
Earnings Quality
80
Growth
56
Value
68
Momentum
84
Safety
50
Cash Flow
69
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. MD scores highest in Momentum (84/100) and lowest in Profitability (43/100). An overall grade of A places MD among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
2.12
Grey Zone
Piotroski F-Score
8/9
Beneish M-Score
-2.79
Unlikely Manipulator
Ohlson O-Score
-7.57
Bankruptcy prob: 0.1%
Low Risk
Credit Rating
A-
Score: 67.5/100
Trend: Improving
Earnings Quality
100/100
OCF/NI: 1.49x
Accruals: -3.9%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. MD scores 2.12, placing it in the Grey Zone (safe > 2.99, distress < 1.81). Financial distress is possible and warrants monitoring. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. MD scores 8/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. MD's score of -2.79 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. MD's implied 0.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. MD receives an estimated rating of A- (score: 67.5/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). MD's score of 100/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
10.14x
PEG
0.02x
P/S
0.90x
P/B
2.01x
P/FCF
7.48x
P/OCF
6.86x
EV/EBITDA
6.94x
EV/Revenue
1.00x
EV/EBIT
7.56x
EV/FCF
8.15x
Earnings Yield
9.80%
FCF Yield
13.37%
Shareholder Yield
6.00%
Graham Number
$22.18
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 10.1x earnings, MD trades at a reasonable valuation. An earnings yield of 9.8% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $22.18 per share, suggesting a potential 4% margin of safety at the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.767
NI / EBT
×
Interest Burden
0.886
EBT / EBIT
×
EBIT Margin
0.133
EBIT / Rev
×
Asset Turnover
0.878
Rev / Assets
×
Equity Multiplier
2.698
Assets / Equity
=
ROE
21.4%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. MD's ROE of 21.4% is driven by Asset Turnover (0.878), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
19.28%
Fair P/E
47.06x
Intrinsic Value
$98.69
Price/Value
0.22x
Margin of Safety
78.33%
Premium
-78.33%
Assessment
Undervalued
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with MD's realized 19.3% 3-year EPS CAGR — what the company actually delivered, not what analysts hope for. At an intrinsic value of $98.69, MD appears undervalued with a 78% margin of safety. The adjusted fair P/E of 47.1x compares to the current market P/E of 10.1x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$21.27
Median 1Y
$18.03
5th Pctile
$7.79
95th Pctile
$41.76
Ann. Volatility
51.3%
Analyst Target
$24.50
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Mark S. Ordan
Chief Executive Officer
$970,014 $8,456,024 $14,140,217
Don Gregory Neeb
Executive Vice President, Chief Investment & Strategy Officer
$229,167 $3,569,243 $5,317,268
Mary Ann E.
Moore Executive Vice President, General Counsel, Chief Administrative Officer and Secretary
$500,000 $1,391,936 $3,031,152
James D. Swift,
M.D. Former Chief Executive Officer
$54,167 $730,720 $2,775,881
Kasandra H. Rossi
Executive Vice President, Chief Financial Officer & Treasurer
$437,500 $598,276 $1,860,037

CEO Pay Ratio

23:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $14,140,217
Avg Employee Cost (SGA/emp): $601,978
Employees: 400

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
400
-81.4% YoY
Revenue / Employee
$4,784,623
Rev: $1,913,849,000
Profit / Employee
$413,470
NI: $165,388,000
SGA / Employee
$601,978
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -4.7% 1.7% 15.9% 11.2% 10.3% 10.2% 7.4% 11.4% 11.5% 10.5% -6.9% -8.1% -28.9% -29.2% -12.3% -10.2% 13.6% 20.1% 20.3% 21.4% 21.37%
ROA -1.4% 0.5% 4.3% 3.0% 2.8% 2.8% 2.6% 4.0% 4.1% 3.7% -2.6% -3.1% -11.0% -11.1% -4.5% -3.8% 5.0% 7.4% 7.5% 7.9% 7.92%
ROIC 7.0% 9.9% 11.0% 11.2% 10.7% 10.2% 8.8% 8.1% 8.1% 7.6% 0.4% -0.4% -12.3% -12.6% -5.0% -3.8% 11.9% 14.7% 16.0% 17.1% 17.12%
ROCE 4.9% 5.9% 8.9% 7.4% 7.2% 6.7% 6.3% 8.7% 8.6% 8.2% -0.5% -1.1% -12.4% -12.7% -3.5% -2.4% 10.5% 13.7% 13.8% 14.3% 14.34%
Gross Margin 27.9% 28.0% 27.7% 22.9% 25.8% 23.5% 22.5% 20.0% 23.1% 21.1% 20.4% 19.2% 22.6% 22.9% 25.6% 22.4% 26.6% 28.5% 24.4% 23.7% 23.72%
Operating Margin 10.6% 11.9% 13.6% 8.1% 10.3% 9.7% 7.0% 6.1% 9.7% 7.9% -22.5% 3.2% -31.3% 6.6% 7.8% 7.0% 12.8% 13.8% 11.1% 9.8% 9.78%
Net Margin 7.4% 6.2% 9.5% -4.4% 5.6% 6.3% 5.8% 2.9% 5.6% 4.2% -25.0% 0.8% -30.3% 3.8% 6.1% 4.5% 8.4% 14.5% 6.8% 6.2% 6.21%
EBITDA Margin 13.3% 14.0% 15.6% -1.6% 12.4% 11.7% 9.1% 7.9% 11.5% 10.0% -24.1% 5.8% -29.5% 8.1% 9.9% 9.3% 14.8% 19.6% 12.1% 11.2% 11.18%
FCF Margin 5.7% -0.8% 2.3% 1.6% 3.2% 4.5% 7.0% 6.8% 7.0% 6.6% 5.2% 4.1% 5.0% 5.7% 9.2% 9.8% 11.7% 14.2% 13.2% 12.3% 12.30%
OCF Margin 7.2% 1.1% 4.0% 3.2% 4.6% 5.7% 8.5% 8.3% 8.5% 8.3% 6.9% 5.7% 6.5% 7.1% 10.3% 10.8% 12.6% 15.1% 14.2% 13.4% 13.41%
ROE 3Y Avg snapshot only 0.35%
ROE 5Y Avg snapshot only 4.55%
ROA 3Y Avg snapshot only 0.25%
ROIC 3Y Avg snapshot only 2.60%
ROIC Economic snapshot only 11.81%
Cash ROA snapshot only 11.53%
Cash ROIC snapshot only 25.24%
CROIC snapshot only 23.15%
NOPAT Margin snapshot only 9.10%
Pretax Margin snapshot only 11.76%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 12.55%
SBC / Revenue snapshot only 0.62%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -49.17 127.80 17.96 21.77 21.35 16.23 18.58 12.07 11.42 11.27 -12.93 -11.83 -2.50 -3.86 -11.37 -15.10 11.34 8.84 10.92 10.20 10.142
P/S Ratio 1.44 1.34 1.23 1.03 0.92 0.70 0.63 0.62 0.59 0.52 0.39 0.42 0.31 0.49 0.56 0.63 0.64 0.75 0.94 0.92 0.904
P/B Ratio 3.47 3.27 2.62 2.24 2.01 1.52 1.38 1.38 1.32 1.18 0.92 0.98 0.74 1.15 1.47 1.63 1.63 1.87 2.09 2.05 2.011
P/FCF 25.29 -158.68 52.86 64.48 28.62 15.41 8.98 9.16 8.45 7.90 7.51 10.27 6.27 8.50 6.10 6.40 5.49 5.25 7.15 7.48 7.477
P/OCF 20.01 118.62 30.64 32.64 19.93 12.15 7.38 7.51 6.90 6.32 5.69 7.39 4.81 6.86 5.45 5.80 5.10 4.94 6.66 6.86 6.860
EV/EBITDA 18.33 14.86 12.41 12.77 11.91 10.36 11.78 9.05 8.91 8.61 48.08 80.50 -6.09 -7.59 -50.77 -107.19 7.67 6.77 7.33 6.94 6.945
EV/Revenue 1.76 1.65 1.53 1.33 1.21 0.99 0.94 0.93 0.90 0.83 0.65 0.68 0.58 0.75 0.72 0.79 0.80 0.91 1.03 1.00 1.003
EV/EBIT 22.34 17.63 14.37 15.26 14.32 12.68 15.25 10.98 10.86 10.59 -144.64 -65.84 -5.09 -6.47 -23.77 -37.27 8.68 7.43 7.98 7.56 7.557
EV/FCF 30.92 -196.02 65.87 83.09 37.83 21.94 13.46 13.75 12.87 12.50 12.55 16.71 11.48 13.05 7.80 8.01 6.87 6.39 7.78 8.15 8.152
Earnings Yield -2.0% 0.8% 5.6% 4.6% 4.7% 6.2% 5.4% 8.3% 8.8% 8.9% -7.7% -8.5% -40.0% -25.9% -8.8% -6.6% 8.8% 11.3% 9.2% 9.8% 9.80%
FCF Yield 4.0% -0.6% 1.9% 1.6% 3.5% 6.5% 11.1% 10.9% 11.8% 12.7% 13.3% 9.7% 16.0% 11.8% 16.4% 15.6% 18.2% 19.1% 14.0% 13.4% 13.37%
PEG Ratio snapshot only 0.024
EV/OCF snapshot only 7.479
EV/Gross Profit snapshot only 3.888
Acquirers Multiple snapshot only 8.455
Shareholder Yield snapshot only 6.00%
Graham Number snapshot only $22.18
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 3.49 3.49 1.97 1.97 1.97 1.97 1.00 1.00 1.00 1.00 1.24 1.24 1.24 1.24 1.47 1.47 1.47 1.47 1.66 1.66 1.664
Quick Ratio 3.49 3.49 1.97 1.97 1.97 1.97 1.00 1.00 1.00 1.00 1.24 1.24 1.24 1.24 1.47 1.47 1.47 1.47 1.66 1.66 1.664
Debt/Equity 2.41 2.41 1.19 1.19 1.19 1.19 0.80 0.80 0.80 0.80 0.83 0.83 0.83 0.83 0.87 0.87 0.87 0.87 0.76 0.76 0.763
Net Debt/Equity 0.77 0.77 0.65 0.65 0.65 0.65 0.69 0.69 0.69 0.69 0.62 0.62 0.62 0.62 0.41 0.41 0.41 0.41 0.19 0.19 0.185
Debt/Assets 0.54 0.54 0.39 0.39 0.39 0.39 0.31 0.31 0.31 0.31 0.32 0.32 0.32 0.32 0.31 0.31 0.31 0.31 0.29 0.29 0.294
Debt/EBITDA 10.45 8.87 4.51 5.27 5.34 5.68 4.58 3.52 3.57 3.70 25.85 41.56 -3.71 -3.54 -23.34 -45.59 3.25 2.56 2.46 2.37 2.367
Net Debt/EBITDA 3.33 2.83 2.45 2.86 2.90 3.08 3.92 3.02 3.06 3.17 19.30 31.03 -2.77 -2.65 -11.06 -21.60 1.54 1.21 0.60 0.58 0.576
Interest Coverage 1.59 2.16 2.97 2.69 3.05 3.31 3.05 4.38 4.01 3.76 -0.21 -0.49 -5.48 -5.65 -1.49 -1.06 4.72 7.57 8.19 8.78 8.782
Equity Multiplier 4.48 4.48 3.04 3.04 3.04 3.04 2.63 2.63 2.63 2.63 2.61 2.61 2.61 2.61 2.81 2.81 2.81 2.81 2.59 2.59 2.595
Cash Ratio snapshot only 1.089
Debt Service Coverage snapshot only 9.557
Cash to Debt snapshot only 0.757
FCF to Debt snapshot only 0.360
Defensive Interval snapshot only 1006.0 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.48 0.49 0.63 0.64 0.65 0.64 0.78 0.78 0.79 0.79 0.87 0.88 0.88 0.88 0.92 0.90 0.89 0.88 0.87 0.88 0.878
Inventory Turnover
Receivables Turnover 5.31 5.41 7.03 7.16 7.21 7.20 6.59 6.62 6.67 6.72 7.01 7.02 7.04 7.05 7.56 7.43 7.29 7.22 7.82 7.89 7.890
Payables Turnover 27.82 28.29 29.00 29.63 30.03 30.44 43.94 44.56 45.28 46.01 47.35 47.57 47.72 47.56 38.47 37.38 36.24 35.21 34.09 34.27 34.268
DSO 69 67 52 51 51 51 55 55 55 54 52 52 52 52 48 49 50 51 47 46 46.3 days
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 13 13 13 12 12 12 8 8 8 8 8 8 8 8 9 10 10 10 11 11 10.7 days
Cash Conversion Cycle 56 55 39 39 38 39 47 47 47 46 44 44 44 44 39 39 40 40 36 36 35.6 days
Fixed Asset Turnover snapshot only 26.278
Cash Velocity snapshot only 3.866
Capital Intensity snapshot only 1.163
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue -32.2% -17.7% 10.2% 11.9% 9.1% 7.0% 3.2% 1.8% 1.8% 2.8% 1.1% 0.9% 0.4% -0.3% 0.9% -1.1% -3.1% -4.2% -4.9% -2.3% -2.25%
Net Income 97.3% 1.0% 1.2% 1.1% 2.6% 3.4% -49.3% 10.4% 22.1% 11.1% -1.9% -1.7% -3.4% -3.7% -64.0% -16.7% 1.4% 1.6% 2.7% 3.1% 3.12%
EPS 97.4% 1.0% 1.2% 1.1% 2.6% 3.6% -47.2% 14.6% 26.5% 10.9% -1.9% -1.7% -3.4% -3.7% -60.5% -13.3% 1.4% 1.6% 2.7% 3.2% 3.18%
FCF -66.8% -1.0% -75.2% -87.0% -38.6% 6.7% 2.1% 3.3% 1.2% 50.5% -24.2% -39.3% -27.8% -13.7% 77.5% 1.4% 1.3% 1.4% 36.9% 22.3% 22.30%
EBITDA -25.2% 7.9% 61.6% 30.4% 15.5% -7.7% -33.6% 0.6% 0.5% 3.2% -82.7% -91.7% -1.9% -2.0% -2.0% -1.9% 2.1% 2.3% 10.5% 20.2% 20.21%
Op. Income 1.1% 28.1% 1.1% 90.4% 67.6% 22.4% -14.9% -24.2% -25.0% -24.3% -95.8% -1.0% -2.3% -2.4% -10.4% -6.7% 1.8% 1.9% 4.1% 5.4% 5.36%
OCF Growth snapshot only 20.86%
Asset Growth snapshot only 4.37%
Equity Growth snapshot only 13.19%
Debt Growth snapshot only -0.30%
Shares Change snapshot only -3.19%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y -20.7% -20.4% -19.4% -18.5% -18.0% -17.9% -17.5% -13.9% -9.0% -3.3% 4.8% 4.7% 3.7% 3.1% 1.7% 0.5% -0.3% -0.6% -1.0% -0.8% -0.83%
Revenue 5Y -9.7% -10.0% -9.7% -9.8% -10.1% -10.3% -10.6% -10.9% -11.1% -11.1% -11.4% -11.1% -10.8% -10.7% -10.5% -8.6% -6.0% -2.9% 2.0% 2.1% 2.12%
EPS 3Y -61.1% -20.7% 8.7% 23.0% 34.8% 19.3% 19.28%
EPS 5Y -42.8% -15.3% -20.3% -20.8% -18.5% -25.2% -18.9% -19.5% -21.5%
Net Income 3Y -61.8% -21.3% 9.3% 24.4% 35.6% 19.6% 19.64%
Net Income 5Y -43.7% -16.6% -21.6% -22.1% -20.3% -27.0% -20.9% -21.5% -23.0%
EBITDA 3Y -33.8% -29.6% -25.4% -26.5% -24.1% -22.0% -23.3% -11.1% -4.6% 0.9% -42.9% -52.3% 0.6% 11.2% 19.6% 11.1% 11.10%
EBITDA 5Y -23.3% -21.0% -18.6% -20.8% -20.5% -20.7% -23.1% -19.0% -19.5% -19.8% -45.6% -49.4% -2.5% 6.5% 12.9% 12.5% 12.46%
Gross Profit 3Y -22.5% -21.7% -19.7% -18.4% -17.8% -18.8% -19.4% -16.8% -12.8% -8.4% -2.1% -2.7% -4.1% -4.0% -4.0% -3.8% -2.6% 0.5% 1.5% 3.1% 3.12%
Gross Profit 5Y -13.8% -13.9% -13.1% -12.9% -13.0% -13.4% -14.1% -14.7% -15.2% -15.4% -15.7% -15.2% -14.7% -14.1% -12.6% -10.2% -6.7% -2.6% 1.7% 1.9% 1.90%
Op. Income 3Y -35.7% -29.0% -23.1% -19.9% -16.5% 5.8% -57.9% -8.6% -0.9% 7.5% 11.9% 11.89%
Op. Income 5Y -25.8% -22.0% -18.7% -17.2% -16.4% -16.3% -18.5% -19.3% -19.7% -19.8% -56.0% 8.8% 17.0% 15.1% 15.10%
FCF 3Y -34.4% -43.1% -53.3% -40.1% -34.2% -25.0% -17.2% -23.3% -26.0% -16.6% -30.2% -0.7% 60.7% 84.2% 53.4% 45.5% 22.6% 21.1% 21.06%
FCF 5Y -22.2% -35.7% -40.4% -31.0% -26.2% -21.6% -18.4% -17.5% -15.1% -15.5% -23.2% -19.2% -18.0% -10.7% -3.8% -5.9% -3.6% 7.1% -0.2% -0.17%
OCF 3Y -32.3% -61.4% -35.8% -43.8% -35.2% -31.3% -22.2% -15.3% -20.5% -22.0% -12.4% -24.7% 0.4% 90.6% 39.1% 51.7% 39.4% 37.1% 17.5% 16.6% 16.58%
OCF 5Y -19.9% -45.2% -29.6% -33.0% -27.2% -24.1% -20.1% -17.2% -16.4% -14.2% -13.9% -20.1% -16.9% -16.2% -10.2% -4.5% -6.3% -3.8% 5.8% -0.4% -0.40%
Assets 3Y -17.1% -17.1% -22.9% -22.9% -22.9% -22.9% -17.3% -17.3% -17.3% -17.3% -12.8% -12.8% -12.8% -12.8% -7.5% -7.5% -7.5% -7.5% -1.5% -1.5% -1.46%
Assets 5Y -5.9% -5.9% -12.6% -12.6% -12.6% -12.6% -16.7% -16.7% -16.7% -16.7% -17.9% -17.9% -17.9% -17.9% -12.3% -12.3% -12.3% -12.3% -7.7% -7.7% -7.67%
Equity 3Y -37.5% -37.5% -33.8% -33.8% -33.8% -33.8% -15.9% -15.9% -15.9% -15.9% 4.3% 4.3% 4.3% 4.3% -5.2% -5.2% -5.2% -5.2% -1.0% -1.0% -0.97%
Book Value 3Y -35.7% -36.3% -33.3% -33.5% -34.3% -33.8% -15.5% -15.7% -15.5% -15.6% 5.0% 5.3% 5.4% 5.0% -4.9% -5.3% -5.6% -6.2% -1.6% -1.3% -1.27%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.36 0.46 0.48 0.62 0.73 0.73 0.65 0.74 0.79 0.71 0.54 0.54 0.56 0.57 0.61 0.64 0.67 0.69 0.46 0.47 0.474
Earnings Stability 0.31 0.22 0.18 0.21 0.06 0.01 0.01 0.00 0.01 0.10 0.09 0.21 0.15 0.55 0.58 0.59 0.41 0.33 0.36 0.38 0.383
Margin Stability 0.88 0.89 0.90 0.91 0.92 0.93 0.93 0.92 0.92 0.91 0.90 0.90 0.89 0.90 0.91 0.91 0.91 0.91 0.92 0.91 0.910
Rev. Growth Consistency 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.50 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.500
FCF Positive Streak 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.50 0.20 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.96 0.20 0.20 0.20 0.20 0.50 0.50 0.20 0.20 0.20 0.20 0.200
Earnings Smoothness 0.00 0.34 0.90 0.80 0.89
ROE Trend 0.60 0.50 1.18 1.04 0.78 0.32 0.53 0.57 0.10 0.05 -0.18 -0.19 -0.40 -0.40 -0.13 -0.12 0.23 0.31 0.29 0.30 0.297
Gross Margin Trend 0.01 0.01 0.01 0.01 0.00 -0.01 -0.03 -0.03 -0.04 -0.04 -0.04 -0.04 -0.03 -0.02 0.00 0.01 0.03 0.04 0.04 0.04 0.036
FCF Margin Trend -0.04 -0.13 -0.07 -0.09 -0.05 -0.02 0.01 -0.01 0.03 0.05 0.01 -0.00 -0.00 0.00 0.03 0.04 0.06 0.08 0.06 0.05 0.054
Sustainable Growth Rate 1.7% 15.9% 11.2% 10.3% 10.2% 7.4% 11.4% 11.5% 10.5% 13.6% 20.1% 20.3% 21.4% 21.37%
Internal Growth Rate 0.5% 4.5% 3.1% 2.9% 2.9% 2.7% 4.2% 4.2% 3.8% 5.3% 8.0% 8.1% 8.6% 8.60%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income -2.46 1.08 0.59 0.67 1.07 1.34 2.52 1.61 1.65 1.78 -2.27 -1.60 -0.52 -0.56 -2.09 -2.60 2.22 1.79 1.64 1.49 1.487
FCF/OCF 0.79 -0.75 0.58 0.51 0.70 0.79 0.82 0.82 0.82 0.80 0.76 0.72 0.77 0.81 0.89 0.91 0.93 0.94 0.93 0.92 0.917
FCF/Net Income snapshot only 1.364
OCF/EBITDA snapshot only 0.929
CapEx/Revenue 1.5% 2.0% 1.7% 1.6% 1.4% 1.2% 1.5% 1.5% 1.6% 1.7% 1.7% 1.6% 1.5% 1.4% 1.1% 1.0% 0.9% 0.9% 1.0% 1.1% 1.11%
CapEx/Depreciation snapshot only 0.946
Accruals Ratio -0.05 -0.00 0.02 0.01 -0.00 -0.01 -0.04 -0.02 -0.03 -0.03 -0.09 -0.08 -0.17 -0.17 -0.14 -0.14 -0.06 -0.06 -0.05 -0.04 -0.039
Sloan Accruals snapshot only 0.035
Cash Flow Adequacy snapshot only 12.113
Earnings Quality Score snapshot only 1.000
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Total Payout Ratio 24.6% 3.6% 4.2% 80.7% 1.0% 1.3% 86.6% 23.1% 2.6% 2.3% 14.4% 52.4% 61.2% 61.17%
Div. Increase Streak
Chowder Number
Buyback Yield 0.3% 0.2% 0.2% 0.2% 3.8% 6.4% 7.2% 7.2% 2.0% 0.2% 0.1% 0.1% 0.2% 0.1% 0.2% 0.2% 0.2% 1.6% 4.8% 6.0% 6.00%
Net Buyback Yield 0.1% -0.1% -0.1% -0.2% 3.4% 6.0% 6.7% 6.7% 1.6% -0.3% -0.5% -0.4% -0.5% -0.3% -0.2% -0.1% -0.1% 1.4% 4.7% 5.9% 5.86%
Total Shareholder Return 0.1% -0.1% -0.1% -0.2% 3.4% 6.0% 6.7% 6.7% 1.6% -0.3% -0.5% -0.4% -0.5% -0.3% -0.2% -0.1% -0.1% 1.4% 4.7% 5.9% 5.86%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) -1.00 0.21 0.97 0.87 0.75 0.79 0.82 0.78 0.81 0.79 1.25 1.15 0.94 0.93 0.98 1.02 0.78 0.79 0.76 0.77 0.767
Interest Burden (EBT/EBIT) 0.37 0.54 0.66 0.63 0.67 0.70 0.67 0.78 0.77 0.75 5.36 2.97 1.18 1.18 1.67 1.94 0.79 0.87 0.88 0.89 0.886
EBIT Margin 0.08 0.09 0.11 0.09 0.08 0.08 0.06 0.08 0.08 0.08 -0.00 -0.01 -0.11 -0.12 -0.03 -0.02 0.09 0.12 0.13 0.13 0.133
Asset Turnover 0.48 0.49 0.63 0.64 0.65 0.64 0.78 0.78 0.79 0.79 0.87 0.88 0.88 0.88 0.92 0.90 0.89 0.88 0.87 0.88 0.878
Equity Multiplier 3.34 3.34 3.69 3.69 3.69 3.69 2.84 2.84 2.84 2.84 2.62 2.62 2.62 2.62 2.71 2.71 2.71 2.71 2.70 2.70 2.698
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-0.61 $0.22 $1.52 $1.08 $0.98 $1.02 $0.80 $1.24 $1.24 $1.13 $-0.72 $-0.85 $-3.02 $-3.00 $-1.15 $-0.96 $1.27 $1.89 $1.96 $2.10 $2.10
Book Value/Share $8.70 $8.68 $10.37 $10.50 $10.47 $10.83 $10.75 $10.83 $10.79 $10.75 $10.11 $10.20 $10.19 $10.05 $8.91 $8.91 $8.81 $8.93 $10.26 $10.42 $10.58
Tangible Book/Share $-8.81 $-8.79 $-7.30 $-7.38 $-7.36 $-7.62 $-7.94 $-8.00 $-7.97 $-7.94 $-6.62 $-6.68 $-6.68 $-6.58 $-5.70 $-5.70 $-5.63 $-5.71 $-4.88 $-4.96 $-4.96
Revenue/Share $20.91 $21.25 $22.11 $22.79 $22.89 $23.64 $23.77 $24.06 $24.14 $24.26 $23.74 $24.00 $24.03 $23.74 $23.44 $23.03 $22.34 $22.46 $22.67 $23.25 $23.25
FCF/Share $1.19 $-0.18 $0.51 $0.36 $0.73 $1.07 $1.65 $1.63 $1.68 $1.61 $1.24 $0.98 $1.21 $1.36 $2.15 $2.26 $2.61 $3.19 $2.99 $2.86 $2.86
OCF/Share $1.51 $0.24 $0.89 $0.72 $1.05 $1.36 $2.01 $1.99 $2.06 $2.01 $1.63 $1.36 $1.57 $1.69 $2.41 $2.50 $2.82 $3.39 $3.21 $3.12 $3.12
Cash/Share $14.30 $14.27 $5.64 $5.70 $5.69 $5.88 $1.24 $1.25 $1.25 $1.24 $2.12 $2.13 $2.13 $2.10 $4.06 $4.06 $4.01 $4.07 $5.92 $6.02 $3.96
EBITDA/Share $2.01 $2.36 $2.73 $2.37 $2.33 $2.27 $1.89 $2.47 $2.43 $2.34 $0.32 $0.20 $-2.27 $-2.34 $-0.33 $-0.17 $2.34 $3.02 $3.18 $3.36 $3.36
Debt/Share $21.00 $20.96 $12.33 $12.48 $12.45 $12.88 $8.65 $8.71 $8.67 $8.64 $8.35 $8.43 $8.42 $8.30 $7.71 $7.72 $7.63 $7.74 $7.82 $7.95 $7.95
Net Debt/Share $6.70 $6.69 $6.70 $6.78 $6.76 $6.99 $7.40 $7.46 $7.43 $7.40 $6.24 $6.29 $6.29 $6.20 $3.65 $3.66 $3.61 $3.67 $1.90 $1.93 $1.93
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 2.119
Altman Z-Prime snapshot only 2.887
Piotroski F-Score 5 6 5 5 6 6 5 6 6 5 4 4 4 5 5 5 6 6 7 8 8
Beneish M-Score -3.33 -3.08 -2.10 -2.08 -2.11 -2.08 -2.57 -2.55 -2.57 -2.59 -2.95 -2.94 -3.36 -3.45 -3.35 -3.27 -2.92 -2.94 -2.80 -2.79 -2.793
Ohlson O-Score snapshot only -7.574
Net-Net WC snapshot only $-7.43
EVA snapshot only $73101277.70
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only A-
Credit Score 34.54 35.69 44.90 38.13 43.84 44.66 46.05 47.55 47.11 47.12 24.21 24.18 34.35 33.92 40.17 40.72 51.37 66.24 68.10 67.54 67.542
Credit Grade snapshot only 7
Credit Trend snapshot only 26.817
Implied Spread (bps) snapshot only 175.000
Industry Credit Rank snapshot only 64
Sector Credit Rank snapshot only 63

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms